Good Tolerance of Citrate Accumulation due to Plasma Exchange among Patients with Acute-on-Chronic Liver Failure: A Prospective, Observational Study
Table 2
Immediate effect of the first session of ALSS therapy.
Rate of reduction between pre- and post-ALSS therapy (%)
Rate of reduction between pre-ALSS therapy and the next morning (%)
Hemoglobin
12.1 ± 6.3
3.3 ± 5.9
Platelets
20.0 ± 18.1
17.4 ± 15.3
White blood cells
−7.3 ± 31.6
7.1 ± 21.5
INR
12.7 ± 17.8
9.4 ± 15.2
Total bilirubin
49.1 ± 6.7
14.1 ± 14.8
Direct bilirubin
47.5 ± 7.2
16.8 ± 9.8
Alanine transaminase
36.9 ± 12.2
27.4 ± 13.5
Aspartate transaminase
30.4 ± 57.8
17.1 ± 11.3
Alkaline phosphatase
24.9 ± 33.6
3.2 ± 61.3
gamma-Glutamyl transferase
31.2 ± 14.1
20.0 ± 18.8
Albumin
5.6 ± 7.6
−2.2 ± 8.9
Globulin
13.4 ± 12.3
12.7 ± 8.6
Total bile acid
19.9 ± 14.1
28.5 ± 14.4
Creatinine
7.7 ± 15.4
3.2 ± 16.6
Ammonia
16.3 ± 36.3
−32.5 ± 68.3
Sodium
−3.1 ± 2.5
−1.9 ± 2.4
Potassium
−6.3 ± 10.0
−10.6 ± 14.0
Chloride
−1.2 ± 4.7
−0.3 ± 4.5
MELD score
21.4 ± 13.4
9.2 ± 10.2
ALSS, artificial liver support system; MELD, model for end-stage liver disease; INR, international normalized ratio; measurement data are represented as mean ± SD.
